Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Declines By 37.5%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 24,300 shares, a decline of 37.5% from the February 28th total of 38,900 shares. Based on an average trading volume of 138,100 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of equities analysts recently commented on BOLT shares. Stifel Nicolaus lowered their price target on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research report on Tuesday. HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Tuesday. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bolt Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $1.13.

Bolt Biotherapeutics Price Performance

Bolt Biotherapeutics stock traded down $0.01 during trading hours on Friday, reaching $0.43. 202,395 shares of the stock were exchanged, compared to its average volume of 171,895. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. Bolt Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $1.56. The company has a market cap of $16.29 million, a P/E ratio of -0.25 and a beta of 0.94. The stock has a 50 day moving average of $0.47 and a two-hundred day moving average of $0.55.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.38) EPS for the quarter, meeting the consensus estimate of ($0.38). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. Equities analysts expect that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Trading of Bolt Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new position in Bolt Biotherapeutics in the fourth quarter valued at about $25,000. Squarepoint Ops LLC bought a new stake in shares of Bolt Biotherapeutics during the 4th quarter valued at approximately $26,000. Velan Capital Investment Management LP acquired a new position in Bolt Biotherapeutics during the 4th quarter worth approximately $27,000. Citadel Advisors LLC acquired a new position in Bolt Biotherapeutics during the 4th quarter worth approximately $42,000. Finally, FMR LLC lifted its stake in Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the last quarter. 86.70% of the stock is currently owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.